entertainment -WSS

entertainment

author：comprehensive 2025-09-30 17:02:56 - browse：1734

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Boston's new lab space is opening empty

WSS

NIH launches clinical trials and new research office for long Covid

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

The high personal cost of affirmative action for Black doctors

What the US credit downgrade means for the economy, your finances

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

hotspot

entertainment

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: CAR

Affirmative action in medical school literally saved lives

The high personal cost of affirmative action for Black doctors

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Medical leaders decry Supreme Court decision on affirmative action

Boston's new lab space is opening empty

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Trump indictment: Who are the 'co

entertainment

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

UCLA team creates talking throat patch for voice disorders

Vertex non

Amazon expands telehealth clinic nationwide

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

knowledge

leisure time

entertainment

focus